These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7530943)

  • 21. Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia.
    Lepor H
    Urol Clin North Am; 1990 Aug; 17(3):651-9. PubMed ID: 1695785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Surgery (TUR-P) as a recommended initial treatment modality for the presented case].
    Gotoh M
    Hinyokika Kiyo; 2005 Sep; 51(9):603-8. PubMed ID: 16229373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
    Miner M; Rosenberg MT; Perelman MA
    Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Embryologic development of the prostate. Insights into the etiology and treatment of benign prostatic hyperplasia.
    Shapiro E
    Urol Clin North Am; 1990 Aug; 17(3):487-93. PubMed ID: 1695777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current treatment of BPH.
    Roylance P; Gibelin B; Espié J
    Biomed Pharmacother; 1995; 49(7-8):332-8. PubMed ID: 8562858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New conservative therapeutic approaches in benign prostatic hyperplasia].
    Schulze H; Berges R; Paschold K; Senge T
    Urologe A; 1992 Jan; 31(1):8-13. PubMed ID: 1372777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
    Chapple CR
    BJU Int; 2004 Sep; 94(5):738-44. PubMed ID: 15329091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha blockade for the treatment of benign prostatic hyperplasia.
    Lepor H
    Urol Clin North Am; 1995 May; 22(2):375-86. PubMed ID: 7539182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Conservative, non-hormonal treatment of benign prostatic hyperplasia].
    Dreikorn K; Richter R; Schönhöfer PS
    Urologe A; 1990 Jan; 29(1):8-16; discussion 17-8. PubMed ID: 1690486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapy of benign prostatic hyperplasia with alpha receptor blockers].
    Stockamp K
    Urologe A; 1995 Jan; 34(1):3-8. PubMed ID: 7533449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
    McVary KT
    J Urol; 2006 Jan; 175(1):35-42. PubMed ID: 16406865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of high-energy transurethral microwave thermotherapy in alleviating medically refractory urinary retention due to benign prostatic hyperplasia.
    Kellner DS; Armenakas NA; Brodherson M; Heyman J; Fracchia JA
    Urology; 2004 Oct; 64(4):703-6. PubMed ID: 15491705
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
    Tanaka Y; Masumori N; Itoh N; Sato Y; Takahashi A; Ogura H; Furuya S; Tsukamoto T
    J Urol; 2002 Jun; 167(6):2492-5. PubMed ID: 11992065
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha1-blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the relevant differences in randomised controlled trials?
    De Mey C
    Eur Urol; 2000; 38 Suppl 1():25-39. PubMed ID: 11111206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Latest frontiers in pharmacotherapy for benign prostatic hyperplasia].
    Kawabe K
    Yakugaku Zasshi; 2006 Mar; 126 Spec no.():199-206. PubMed ID: 16518083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What's best for your patient with BPH?
    Neal RH; Keister D
    J Fam Pract; 2009 May; 58(5):241-7. PubMed ID: 19442387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
    Witjes WP; Rosier PF; Caris CT; Debruyne FM; de la Rosette JJ
    Urology; 1997 Feb; 49(2):197-205; discussion 205-6. PubMed ID: 9037281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Novel therapeutics strategies in benign hypertrophy of prostate management].
    Roumeguère T
    Rev Med Brux; 2005 Sep; 26(4):S407-11. PubMed ID: 16240894
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.